PDS Biotechnology (PDSB) Competitors $0.95 -0.10 (-9.51%) Closing price 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.09%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. SOPH, NGNE, PLX, CTNM, CKPT, LFVN, NMRA, CRGX, AMRN, and TNGXShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include SOPHiA GENETICS (SOPH), Neurogene (NGNE), Protalix BioTherapeutics (PLX), Contineum Therapeutics (CTNM), Checkpoint Therapeutics (CKPT), LifeVantage (LFVN), Neumora Therapeutics (NMRA), CARGO Therapeutics (CRGX), Amarin (AMRN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. SOPHiA GENETICS Neurogene Protalix BioTherapeutics Contineum Therapeutics Checkpoint Therapeutics LifeVantage Neumora Therapeutics CARGO Therapeutics Amarin Tango Therapeutics PDS Biotechnology (NASDAQ:PDSB) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Is PDSB or SOPH more profitable? PDS Biotechnology has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. SOPHiA GENETICS's return on equity of -55.06% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% SOPHiA GENETICS -110.71%-55.06%-38.33% Which has higher earnings and valuation, PDSB or SOPH? PDS Biotechnology has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.03-0.92SOPHiA GENETICS$65.17M2.82-$78.98M-$0.95-2.91 Do insiders & institutionals believe in PDSB or SOPH? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 9.5% of PDS Biotechnology shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, PDSB or SOPH? PDS Biotechnology has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Do analysts rate PDSB or SOPH? PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 847.27%. SOPHiA GENETICS has a consensus price target of $6.80, indicating a potential upside of 146.38%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, equities research analysts clearly believe PDS Biotechnology is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to PDSB or SOPH? In the previous week, PDS Biotechnology had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 3 mentions for PDS Biotechnology and 1 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 1.95 beat PDS Biotechnology's score of 0.16 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in PDSB or SOPH? PDS Biotechnology received 56 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. Likewise, 70.75% of users gave PDS Biotechnology an outperform vote while only 70.37% of users gave SOPHiA GENETICS an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes7570.75% Underperform Votes3129.25% SOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% SummaryPDS Biotechnology beats SOPHiA GENETICS on 11 of the 17 factors compared between the two stocks. Remove Ads Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.13M$6.36B$5.28B$7.12BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.826.7722.8817.49Price / SalesN/A187.41357.2285.14Price / CashN/A65.6738.1634.64Price / Book1.135.586.233.79Net Income-$42.94M$141.89M$3.20B$247.10M7 Day Performance-24.60%-11.26%-7.94%-7.28%1 Month Performance-26.35%-14.38%-2.92%-10.14%1 Year Performance-71.12%-18.22%3.65%-7.35% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.6752 of 5 stars$0.95-9.5%$9.00+847.3%-71.5%$43.13MN/A-0.8220Short Interest ↓Gap DownSOPHSOPHiA GENETICS2.7889 of 5 stars$3.12+3.3%$6.80+117.9%-41.7%$208.06M$65.17M-2.86520Positive NewsNGNENeurogene2.326 of 5 stars$13.96-1.8%$60.80+335.5%-78.0%$207.38M$925,000.000.0090Gap DownPLXProtalix BioTherapeutics1.9617 of 5 stars$2.60+4.4%$15.00+476.9%+109.7%$202.89M$53.40M-20.00200High Trading VolumeCTNMContineum Therapeutics1.4148 of 5 stars$7.76+8.2%$24.80+219.6%N/A$200.77M$50M-1.5831Positive NewsCKPTCheckpoint Therapeutics2.158 of 5 stars$4.05-0.5%$4.33+7.0%+110.4%$197.77M$47,000.00-2.2010Earnings ReportLFVNLifeVantage3.0695 of 5 stars$15.56+0.6%$30.50+96.0%+133.9%$195.29M$212.15M27.79260Gap DownNMRANeumora Therapeutics2.9513 of 5 stars$1.20+6.2%$10.14+745.2%-93.6%$194.38MN/A-0.64108Analyst ForecastCRGXCARGO Therapeutics2.7708 of 5 stars$4.20+0.5%$15.00+257.1%-80.2%$193.42MN/A-0.99116Positive NewsAMRNAmarin0.7356 of 5 stars$0.46+1.6%N/A-60.1%$190.76M$228.61M-5.16360TNGXTango Therapeutics1.8853 of 5 stars$1.74-1.1%$12.33+608.8%-83.5%$188.11M$42.07M-1.4790Positive News Remove Ads Related Companies and Tools Related Companies SOPH Competitors NGNE Competitors PLX Competitors CTNM Competitors CKPT Competitors LFVN Competitors NMRA Competitors CRGX Competitors AMRN Competitors TNGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PDSB Stock Free PDSB Stock Alerts